Completed PHASE2/PHASE3 INTERVENTIONAL NCT00131274

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis

Sponsor: Daniels, Craig E., M.D.

Conditions Idiopathic Pulmonary Fibrosis Lung Disease Pulmonary Fibrosis

Interventions Imatinib Mesylate (Gleevec)

Updated 6 times since 2017 Last updated: Oct 4, 2005 Started: Apr 30, 2003 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Idiopathic Pulmonary Fibrosis and Lung Disease and is currently completed. Daniels, Craig E., M.D. leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daniels, Craig E., M.D.
Novartis

Data source: Daniels, Craig E., M.D.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.